Mazumder et al. used a three-hybrid screen (involving an mRNA and two proteins) to identify the human ribosomal protein L13a -an integral component of the large ribosomal subunit with unknown function -as an inhibitor of the translation of Cp mRNA. L13a was observed to bind to Cp mRNA, but only after 24 hours of IFN-γ treatment, suggesting that an unidentified mechanism delayed its interaction. Insect cells expressing recombinant L13a protein were tested and observed to have Cp translational silencing activity, while Escherichia coli expressing L13a lacked such activity. This, together with the delayed interaction of L13a, suggests that the posttranslational modification of L13a occurs upon IFN-γ treatment, thereby controlling its translational silencing activity.
A modification could explain how an ever-present ribosomal protein could selectively inhibit mRNA only under certain conditions. Mazumder et al. then showed -through the use of phosphatases and metabolic 32 P labeling -that L13a was phosphorylated in a delayed fashion by IFN-γ treatment. In addition, phosphorylation was shown to be necessary for L13a silencing activity. Localization studies showed that phosphorylated L13a was no longer attached to ribosomes, revealing that IFN-γ treatment caused L13a to be released, allowing it to function in Cp translational silencing.
"Our results indicate that the ribosome, in addition to functioning as a protein synthesis machine, also acts as a depot for releasable regulators of protein translation," conclude the authors.
In an accompanying preview article, Robert A. Zimmermann from the University of Massachusetts comments that "perhaps L13a establishes a new paradigm, a translational regulatory 'factor in waiting'; for which... the ribosome merely serves as a convenient depot."
